Status:
UNKNOWN
COVID-19 Antibody Responses in Cystic Fibrosis (CAR-CF)
Lead Sponsor:
Rabin Medical Center
Conditions:
Cystic Fibrosis
Covid19
Eligibility:
All Genders
Brief Summary
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in...
Detailed Description
This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive inf...
Eligibility Criteria
Inclusion
- Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.
- \-
Exclusion
- There are no specific exclusion criteria other than refusal to give informed consent, or contraindication to venepuncture.
- Participants already enrolled in a clinical trial are eligible for enrolment in this study. Inclusion in CAR-CF should not preclude enrolment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).
Key Trial Info
Start Date :
January 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05217784
Start Date
January 25 2022
End Date
January 1 2024
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel